GMAB Stock — Price, Charts & Analysis

Genmab A/S (GMAB) has a trailing P/E of 26.26x and a forward P/E of 20.97x. This places GMAB in a premium earnings multiple territory based on the valuation data currently available on Worldtickers.

GMAB trades with 26.26x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether GMAB looks overvalued or undervalued.

GMAB's P/E of 26.26x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

GMAB's trailing EPS is $1.27 and forward EPS is $1.59. Reported earnings growth is -9.40%, which helps show current profit momentum.

EPS, or earnings per share, shows how much profit Genmab A/S generated for each share. GMAB's trailing EPS is $1.27, and investors usually prefer EPS that is positive and growing over time.

Genmab A/S has a market cap of $20.79B, making GMAB a large-cap stock based on the current market value shown on Worldtickers.

GMAB's latest stock price on Worldtickers is $33.35. The latest move is -$0.06 or -0.18%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

GMAB's quote includes a latest price of $33.35. The market open is $33.36. Previous close is $33.41. The intraday range is $33.29 to $33.98.

GMAB is down in the latest quote, with a move of -$0.06 or -0.18%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

GMAB generated $4.13B in trailing revenue. Revenue growth is 24.90%, which helps show whether demand is expanding or slowing.

GMAB's revenue growth is 24.90%, which is a strong demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, GMAB shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is $788.00M.

Gross margin is 93.03%. Margins show how efficiently Genmab A/S turns revenue into profit.

Genmab A/S carries $5.27B and holds $1.51B in cash.

GMAB holds $1.51B on its balance sheet.

GMAB's book value per share is $9.98.

Institutions hold 16.87% of GMAB shares. Insiders hold 0.00% of shares. Ownership mix helps investors understand how much of Genmab A/S is held by professional investors and company insiders.

GMAB has 623.53M shares outstanding. Float shares are 589.61M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for GMAB, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for GMAB is $1.59. Earnings growth is -9.40%. Revenue growth is 24.90%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

GMAB's trailing EPS is $1.27. Forward EPS is $1.59. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

GMAB is in the Healthcare sector. Its earnings multiple is 26.26x. Its latest displayed growth metric is 24.90%. Compare these figures with sector peers before deciding whether Genmab A/S is stronger or weaker than average.

GMAB trades at $33.35. The stock trades at 26.26x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Genmab A/S's fundamentals.

GMAB risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.69, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

GMAB should be compared with companies in Biotechnology. Its earnings multiple is 26.26x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Genmab A/S (GMAB) operates in Healthcare, specifically Biotechnology. Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, fir

GMAB trades on NasdaqGS. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

GMAB stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Genmab A/S's official website listed on Worldtickers is ir.genmab.com/index.cfm. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Genmab A/S employs about 3.12K people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Genmab A/S is headquartered in Copenhagen, Denmark. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

GMAB is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

GMAB has traded between $23.62 and $35.43 over the past 52 weeks. At $33.35, it is 5.87% below the high and 41.19% above the low. The 52-week range helps gauge long-term price momentum.

GMAB is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is $28.75 and its 200-day moving average is $29.14.

GMAB's RSI is 72.53. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a overbought momentum setup.

GMAB's latest RSI reading is 72.53, which points to overbought momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for GMAB is near $28.03. Key resistance is near $34.19. Breaks above resistance or below support can change the short-term technical setup.

GMAB's nearest reported support level is $28.03. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

GMAB's nearest reported resistance level is $34.19. A breakout above resistance can improve momentum, especially when volume confirms the move.

GMAB trades about 2.12M shares daily on average. The latest displayed volume is 1.69M shares. Volume helps show liquidity and whether trading interest is unusually high or low.

GMAB's MACD is 0.26, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

GMAB is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 72.53 (overbought). MACD is bullish. Nearest support is around $28.03. Resistance is around $34.19. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is $30.75 (8.46% from price). MA50 is $28.75 (15.99% from price). MA200 is $29.14 (14.46% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. GMAB's MA20 is $30.75. MA50 is $28.75. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

GMAB's pivot is near $33.46. Support is near $28.03. Resistance is near $34.19. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for GMAB is near $31.41. The next upper resistance zone is near $34.19. These levels help define risk and possible follow-through zones after a breakout or breakdown.

GMAB's Bollinger range is roughly $27.09 to $34.41. Band width is near 23.82%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

GMAB's ATR-based typical daily range is about 2.50%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 1.69M shares. Average volume is about 2.12M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

GMAB's all-time high shown on Worldtickers is $103.19. Its all-time low is $0.65. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

GMAB has a beta of 0.69, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.